Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Surgery is a primary treatment modality in the intended curative treatment of colorectal liver metastases (CRLM). However, surgery elicits a cascade of potentially detrimental stress responses that may drive the onset of long-term disease progression. Exercise training is emerging as an adjunct treatment in surgical oncology and holds potential to modify the surgical stress response. Against this background, we designed the present randomized controlled trial to evaluate the therapeutic role of pre- and postoperative exercise training in patients with CRLM undergoing open liver resection.
BACKGROUND:
Colorectal cancer is the third most frequent type of cancer in Denmark, with more than 5000 new cases annually. Colorectal liver metastases (CRLM) develop in nearly one fourth of all patients with colorectal cancer, and poses a poor prognostic outlook, with low survival rates and short time to disease progression. Surgical resection, either upfront or following downstaging with perioperative treatments, confers substantial survival benefit in patients with CRLM, and may even comprise a curative treatment modality. However, surgery elicits a cascade of biological responses characterized by increased dissemination of tumor cells and modulation of neuroendocrine, inflammatory, and immunological factors. These local and systemic perturbations typically persist for days to weeks following surgery and may independently or in concert drive the onset of long-term disease progression. Under normal physiological conditions, exercise training is a potent modulator of immune function, systemic inflammation, and the neuroendocrine system, raising the possibility that perioperative exercise training may ameliorate the surgical stress response during and after surgery. However, in a recent systematic review and meta-analysis (submitted), we found that the effects and safety of preoperative and early postoperative exercise are unknown in patients with gastrointestinal cancers (including CRLM) due to lack of studies, widespread methodological issues, and poor ascertainment and reporting of adverse events. Safety is arguably the single most important consideration for the application perioperative exercise, and methodological robust trials evaluating the safety and tolerability of perioperative exercise training along with preliminary information on treatment efficacy are needed to inform the application of exercise in surgical oncology.
Against this background, we designed the present randomized controlled trial to evaluate the therapeutic role of postoperative exercise training in patients with CRLM undergoing open liver resection. The primary trial objective and hypothesis are:
To compare the number of serious adverse events (SAE) in standard care plus postoperative exercise (EX) vs. standard care alone (CON) in patients with colorectal liver metastases scheduled to undergo open liver resection. The primary research hypothesis is that the number of SAEs is non-inferior in EX vs. CON
The key secondary study objectives and hypotheses are:
To compare the effect of EX vs. CON on incidence of postoperative hospital admissions in patients with CRLM undergoing surgery. We hypothesize that the incidence of postoperative hospital admissions are non-inferior in EX vs. CON
To compare the effect of EX vs. CON on relative dose intensity of adjuvant chemotherapy and time from surgery to initiation of adjuvant chemotherapy in patients with CRLM undergoing surgery. We hypothesize that the relative dose intensity of adjuvant chemotherapy and time from surgery to initiation of adjuvant chemotherapy are non-inferior in EX vs. CON.
To compare the effect of EX vs. CON on selected patient-reported symptomatic adverse events in patients with CRLM undergoing surgery
To compare the effect of EX vs. CON on surgical stress responses (neuroendocrine, inflammatory, and immune factors) in patients with CRLM undergoing surgery.
The secondary study objectives are:
To evaluate the feasibility of EX.
To compare the effect of EX vs. CON on functional capacity, muscle strength, aerobic capacity, and body composition in patients with CRLM undergoing surgery.
To compare the effect of EX vs. CON on clinical outcomes in patients with CRLM undergoing surgery.
To compare the effect of EX vs. CON on patient-reported outcomes in patients with CRLM undergoing surgery.
To compare the effect of EX vs. CON on circulating tumor DNA and DNA methylation in patients with CRLM undergoing surgery
To evaluate the effects of acute pre- and postoperative exercise on neuroendocrine, immunological, and inflammatory factors in patients with CRLM undergoing surgery.
To conduct explorative preclinical sub-studies.
TRIAL DESIGN:
This trial is a single-center, randomized, controlled, parallel-group trial performed at Centre for physical Activity (CFAS), Rigshospitalet, Copenhagen, Denmark, and Department of Surgical Gastroenterology, Rigshospitalet, Copenhagen, Denmark.
A total of 60 participants with CRLM will be included and randomly allocated 2:1 to standard care and postoperative exercise training (EX) or standard care alone (CON). The participants will undergo two trial visits at CFAS during the study period: One preoperative trial visit (1-3 days after inclusion and 2-7 days before surgery) and one post-surgery trial visit (8 weeks after discharge). For each visit, the participants will be assessed for body composition and anthropometrics, resting cardiovascular factors, standard blood biochemistry, aerobic capacity (VO2peak, ventilatory threshold), maximal muscle strength, and functional performance. In addition, blood samples will be taken before, during, and immediately after surgery, and on post-operative day 1, 3, and 15 and neuroendocrine, inflammatory, and immune factor will be analyzed. Patient-reported outcomes will be collected at all trial visits and 1, 2, and 3 years after randomization. Data from medical records regarding mortality and disease recurrence will be collected up to 3 years after randomization. As an optional procedure, we will collect blood samples before, during, and after a pre- and a postoperative supervised exercise training session.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Standard care alone (CON) | No Intervention | Participants allocated to CON receive the standard patient care program, as provided by Rigshospitalet, Copenhagen, Denmark. Participants allocated to CON are allowed to exercise on their own initiative or participate in any standard care hospital- or municipality-based exercise training program. | |
| Postoperative exercise training and standard care (EX) | Experimental | Participants allocated to EX receive the standard patient care program, as provided by Rigshospitalet, Copenhagen, Denmark, and postoperative exercise training. The postoperative exercise training program consists of 8 weeks of supervised and home-based exercise 5 times/week. The intensity and duration are progressively increased during the postoperative period |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Exercise training | Behavioral | Perioperative exercise training |
|
| Measure | Description | Time Frame |
|---|---|---|
| Serious adverse events | From discharge to 8 weeks after discharge |
| Measure | Description | Time Frame |
|---|---|---|
| Postoperative hospital admissions | Incidence of postoperative hospital re-admissions, defined as any non-scheduled ≥ 24 h hospitalization | From discharge to 8 weeks after discharge |
| Relative dose intensity (RDI) of adjuvant chemotherapy |
| Measure | Description | Time Frame |
|---|---|---|
| 3-years cancer-specific survival | Proportion of patients who have not died from colorectal cancer 3 years after randomization | Randomization to 3 years after randomization |
| 3-years overall survival | Proportion of patients who are alive 3 years after randomization |
Inclusion Criteria: Participants diagnosed with colorectal liver metastasis planned for open surgery of liver metastases
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Jesper F Christensen, PhD | Centre for Physical Activity Research, Rigshospitalet, University of Copenhagen, Denmark | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Rigshospitalet | Copenhagen | Denmark |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009369 | Neoplasms |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D015444 | Exercise |
| ID | Term |
|---|---|
| D009043 | Motor Activity |
| D009068 | Movement |
| D009142 | Musculoskeletal Physiological Phenomena |
| D055687 | Musculoskeletal and Neural Physiological Phenomena |
Not provided
Not provided
Not provided
Not provided
Not provided
The participants and the exercise intervention instructors cannot be blinded, given the nature of the intervention. The outcome assessors of the primary and key secondary outcomes (adverse events and markers of surgical stress, respectively) will be blinded. For practical reasons, the outcome assessors of the following secondary outcomes will be not be blinded: resting cardiovascular factors, aerobic capacity, muscle strength, functional performance, and body composition and anthropometrics.
RDI (%) of adjuvant chemotherapy, calculated as the actual dose intensity / standard dose intensity x 100%
| From date of planned initiation of adjuvant chemotherapy until 8 weeks after discharge |
| Time to initiation of adjuvant chemotherapy | Time from surgery to initiation of adjuvant chemotherapy | From surgery until 8 weeks after discharge |
| Patient-reported symptomatic adverse events | Patient-reported symptomatic adverse events, assessed using the using the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). | Baseline, 7 days after discharge, 7 days after each administration of adjuvant chemotherapy, 8 weeks after discharge. |
| Surgical stress: IL-1β | Changes in blood IL-1β concentration | Baseline, after last incision, after resection, 3 hour post-surgery, postoperative day 1, postoperative day 3, postoperative day 15, 8 weeks after discharge |
| Surgical stress: IL-6 | Changes in blood IL-6 concentration | Baseline, after last incision, after resection, 3 hour post-surgery, postoperative day 1, postoperative day 3, postoperative day 15, 8 weeks after discharge |
| Surgical stress: IL-8 | Changes in blood IL-8 concentration | Baseline, after last incision, after resection, 3 hour post-surgery, postoperative day 1, postoperative day 3, postoperative day 15, 8 weeks after discharge |
| Surgical stress: IL-10 | Changes in blood IL-10 concentration | Baseline, after last incision, after resection, 3 hour post-surgery, postoperative day 1, postoperative day 3, postoperative day 15, 8 weeks after discharge |
| Surgical stress: interferon- γ | Changes in blood interferon- γ concentration | Baseline, after last incision, after resection, 3 hour post-surgery, postoperative day 1, postoperative day 3, postoperative day 15, 8 weeks after discharge |
| Surgical stress: C-reactive protein | Changes in blood C-reactive protein | Baseline, after last incision, after resection, 3 hour post-surgery, postoperative day 1, postoperative day 3, postoperative day 15, 8 weeks after discharge |
| Surgical stress: Leukocyte differential counts | Changes in blood leukocyte cell counts (total and per type [eosinophils, basophils, lymphocytes, monocytes, neutrophils]) | Baseline, after last incision, after resection, 3 hour post-surgery, postoperative day 1, postoperative day 3, postoperative day 15, 8 weeks after discharge |
| Surgical stress: Natural killer (NK) cells | Changes in blood NK cell count | Baseline, after resection, postoperative day 1, postoperative day 3, postoperative day 15, 8 weeks after discharge |
| Surgical stress: T cells | Changes in blood T cell count | Baseline, after resection, postoperative day 1, postoperative day 3, postoperative day 15, 8 weeks after discharge |
| Surgical stress: Adrenocorticotropic hormone (ACTH) | Changes in blood ACTH concentration | After last incision, after resection, 3 hour post-surgery, postoperative day 1, postoperative day 2, postoperative day 3, postoperative day 15 |
| Surgical stress: Cortisol | Changes in blood cortisol concentration | Baseline, after last incision, after resection, 3 hour post-surgery, postoperative day 1, postoperative day 3, postoperative day 15, 8 weeks after discharge |
| Surgical stress: Adrenaline | Changes in blood adrenaline concentration | Baseline, after last incision, after resection, 3 hour post-surgery, postoperative day 1, postoperative day 3, postoperative day 15, 8 weeks after discharge |
| Surgical stress: Noradrenaline | Changes in blood noradrenaline concentration | Baseline, after last incision, after resection, 3 hour post-surgery, postoperative day 1, postoperative day 3, postoperative day 15, 8 weeks after discharge |
| Randomization to 3 years after randomization |
| Carcinoembryonic antigen (CEA) | Changes in blood CEA | Baseline, postoperative day 15, 8 weeks after discharge |
| Circulating tumor DNA (ctDNA) | Changes in blood ctDNA | Baseline, postoperative day 15, 8 weeks after discharge |
| DNA methylation | Changes in DNA methylation | Baseline, 3 days before surgery, 1 h before anesthesia, after last incision, after resection, 3 hour post-surgery, postoperative day 1, postoperative day 2, postoperative day 3, postoperative day 15, 8 weeks after discharge |
| Exercise feasibility: Exercise sessions attendance rate | Exercise sessions attendance rate (%), defined as number of attended exercise sessions / number of prescribed exercise sessions x 100 | From baseline to 8 weeks after discharge |
| Exercise feasibility: Relative dose intensity (RDI) of exercise | RDI (%) of exercise, defined as prescribed exercise dose / performed exercise dose x 100 | From baseline to 8 weeks after discharge |
| Exercise feasibility: Early termination of exercise sessions | Incidence of early termination of attended exercise sessions, defined as termination of an exercise session before the prescribed exercises have been performed | From baseline to 8 weeks after discharge |
| Exercise feasibility: Exercise intervention interruptions | Incidence of exercise intervention disruptions, defined as a period of ≥ 7 days without an attended exercise session | From baseline to 8 weeks after discharge |
| Exercise feasibility: Exercise sessions requiring dose modifications | Incidence of exercise sessions requiring dose modifications, defined as any deviation from the prescribed exercise | From baseline to 8 weeks after discharge |
| Exercise feasibility: Permanent discontinuation of the exercise intervention | Incidence of permanent discontinuations of the exercise intervention, defined as participants that withdraw entirely from the exercise intervention, regardless of whether they remain in the trial | From baseline to 8 weeks after discharge |
| Exercise feasibility: Time from discharge to initiation of postoperative exercise | Time from discharge to first attended postoperative exercise session | From surgery to 8 weeks after discharge |
| Exercise feasibility: Patient-reported symptomatic adverse events (paint, dizziness, nausea, fatigue, other) | Changes in patient-reported symptomatic adverse events (paint, dizziness, nausea, fatigue, other) | Immediately before and immediately after each exercise session performed from baseline to 8 weeks after discharge |
| Intraoperative factors: Blood loss during surgery | Blood loss during surgery | During surgery |
| Intraoperative factors: Duration of surgery | Duration of surgery | During surgery |
| Intraoperative factors: Blood transfusions | Incidence of blood transfusions | During surgery |
| Resting cardiovascular factors: Resting systolic blood pressure | Changes in resting systolic blood pressure | Baseline, 8 weeks after discharge |
| Resting cardiovascular factors: Resting diastolic blood pressure | Changes in resting diastolic blood pressure | Baseline, 8 weeks after discharge |
| Resting cardiovascular factors: Resting heart rate | Changes in resting heart rate | Baseline, 8 weeks after discharge |
| Resting cardiovascular factors: Hemoglobin concentration | Changes in hemoglobin concentration | Baseline, after last incision, after resection, 3 hour post-surgery, postoperative day 1, postoperative day 2, postoperative day 3, postoperative day 15, 8 weeks after discharge |
| Aerobic capacity: Peak oxygen consumption | Changes in peak oxygen consumption assessed during an incremental exercise test (ergometer bicycling) to volitional exhaustion | Baseline, 8 weeks after discharge |
| Aerobic capacity: Ventilatory threshold | Changes in ventilatory threshold assessed during an incremental exercise test (ergometer bicycling) to volitional exhaustion | Baseline, 8 weeks after discharge |
| Aerobic capacity: Peak power output | Changes in peak power output assessed during an incremental exercise test (ergometer bicycling) to volitional exhaustion | Baseline, 8 weeks after discharge |
| Muscle strength: Leg press maximal muscle strength | Changes in leg press one repetition maximum (1RM) | Baseline, 8 weeks after discharge |
| Muscle strength: Chest press muscle strength | Changes in chest press 1RM | Baseline, 8 weeks after discharge |
| Muscle strength: Hand grip strength | Changes in hand grip strength, assessed using a dynamometer | Baseline, 8 weeks after discharge |
| Functional performance: Habitual gait speed | Changes in habitual gait speed | Baseline, 8 weeks after discharge |
| Functional performance: Maximal gait speed | Changes in maximal gait speed | Baseline, 8 weeks after discharge |
| Functional performance: Stair climbing power | Changes in stair climbing power | Baseline, 8 weeks after discharge |
| Body composition and anthropometrics: Body mass | Changes in body mass | Baseline, 8 weeks after discharge |
| Body composition and anthropometrics: Body mass index | Changes in body mass index | Baseline, 8 weeks after discharge |
| Body composition and anthropometrics: Total lean mass | Changes in total lean mass, assessed by dual energy x-ray absorptiometry (DXA) | Baseline, 8 weeks after discharge |
| Body composition and anthropometrics: Appendicular lean mass | Changes in appendicular lean mass, assessed by DXA | Baseline, 8 weeks after discharge |
| Body composition and anthropometrics: Abdominal fat mass | Changes in abdominal fat mass, assessed by DXA | Baseline, 8 weeks after discharge |
| Body composition and anthropometrics: Total fat mass | Changes in total fat mass, assessed by DXA | Baseline, 8 weeks after discharge |
| Body composition and anthropometrics: Fat percentage | Changes in fat percentage, assessed by DXA | Baseline, 8 weeks after discharge |
| Body composition and anthropometrics: Hip circumference | Changes in hip circumference | Baseline, 8 weeks after discharge |
| Body composition and anthropometrics: Waist circumference | Changes in waist circumference | Baseline, 8 weeks after discharge |
| Standard blood biochemistry: Total cholesterol | Changes in total cholesterol concentration | Baseline, 8 weeks after discharge |
| Standard blood biochemistry: Low-density lipoprotein cholesterol | Changes in low-density lipoprotein cholesterol concentration | Baseline, 8 weeks after discharge |
| Standard blood biochemistry: High-density lipoprotein cholesterol | Changes in high-density lipoprotein cholesterol concentration | Baseline, 8 weeks after discharge |
| Standard blood biochemistry: Triglyceride | Changes in triglyceride concentration | Baseline, 8 weeks after discharge |
| Standard blood biochemistry: Glycated hemoglobin A1c | Change in glycated hemoglobin A1c concentration | Baseline, 8 weeks after discharge |
| Standard blood biochemistry: Insulin | Changes in insulin concentration | Baseline, 8 weeks after discharge |
| Standard blood biochemistry: Glucose | Changes in blood glucose concentration | Baseline, 8 weeks after discharge |
| Health-related quality of life: Physical well-being | Changes in patient-reported physical well-being assessed using the Functional Assessment of Cancer Therapy - Colorectal (FACT-C) | Baseline, 8 weeks after discharge, 1 year after randomization, 2 years after randomization, 3 years after randomization |
| Health-related quality of life: Social well-being | Changes in patient-reported social well-being assessed using the Functional Assessment of Cancer Therapy - Colorectal (FACT-C) | Baseline, 8 weeks after discharge, 1 year after randomization, 2 years after randomization, 3 years after randomization |
| Health-related quality of life: Emotional well-being | Changes in patient-reported emotional well-being assessed using the Functional Assessment of Cancer Therapy - Colorectal (FACT-C). | Baseline, 8 weeks after discharge, 1 year after randomization, 2 years after randomization, 3 years after randomization |
| Health-related quality of life: Functional well-being | Changes in patient-reported functional well-being assessed using the Functional Assessment of Cancer Therapy - Colorectal (FACT-C). | Baseline, 8 weeks after discharge, 1 year after randomization, 2 years after randomization, 3 years after randomization |
| Health-related quality of life: Colorectal-cancer specific | Changes in patient-reported colorectal-cancer specific health-related quality of life assessed using the Functional Assessment of Cancer Therapy - Colorectal (FACT-C). | Baseline, 8 weeks after discharge, 1 year after randomization, 2 years after randomization, 3 years after randomization |
| Health-related quality of life: General | Changes in patient-reported general health-related qualify of life assessed using the Functional Assessment of Cancer Therapy - Colorectal (FACT-C). | Baseline, 8 weeks after discharge, 1 year after randomization, 2 years after randomization, 3 years after randomization |
| Health-related quality of life: Trial outcome index | Changes in patient-reported trial outcome index assessed using the Functional Assessment of Cancer Therapy - Colorectal (FACT-C). | Baseline, 8 weeks after discharge, 1 year after randomization, 2 years after randomization, 3 years after randomization |
| Health-related quality of life: Total score (Functional Assessment of Cancer Therapy - Colorectal) | Changes in patient-reported in health-related quality of life (total score) assessed using the Functional Assessment of Cancer Therapy - Colorectal (FACT-C). | Baseline, 8 weeks after discharge, 1 year after randomization, 2 years after randomization, 3 years after randomization |
| Depression | Changes in patient-reported depression, assessed using the Hospital Anxiety and Depression Scale (HADS). | Baseline, 8 weeks after discharge, 1 year after randomization, 2 years after randomization, 3 years after randomization |
| Anxiety | Changes in patient-reported anxiety, assessed using the Hospital Anxiety and Depression Scale (HADS). | Baseline, 8 weeks after discharge, 1 year after randomization, 2 years after randomization, 3 years after randomization |
| Self-reported physical activity: Walking | Changes in patient-reported weekly duration of walking, assessed using the International Physical Activity Questionnaire (IPAQ) | Baseline, 8 weeks after discharge, 1 year after randomization, 2 years after randomization, 3 years after randomization |
| Self-reported physical activity: Moderate intensity physical activity (PA) | Changes in patient-reported weekly duration of moderate intensity PA, assessed using the International Physical Activity Questionnaire (IPAQ) | Baseline, 8 weeks after discharge, 1 year after randomization, 2 years after randomization, 3 years after randomization |
| Self-reported physical activity: Vigorous intensity physical activity (PA) | Changes in patient-reported weekly duration of vigorous intensity PA, assessed using the International Physical Activity Questionnaire (IPAQ) | Baseline, 8 weeks after discharge, 1 year after randomization, 2 years after randomization, 3 years after randomization |
| Self-reported physical activity: Total physical activity (PA) | Changes in patient-reported weekly duration of total PA, assessed using the International Physical Activity Questionnaire (IPAQ) | Baseline, 8 weeks after discharge, 1 year after randomization, 2 years after randomization, 3 years after randomization |
| Self-reported physical activity: Sitting time | Changes in patient-reported weekly sitting time, assessed using the International Physical Activity Questionnaire (IPAQ) | Baseline, 8 weeks after discharge, 1 year after randomization, 2 years after randomization, 3 years after randomization |
| Effect of acute perioperative exercise: IL-1β | Changes in blood IL-1β concentration during acute perioperative exercise | 10 min before exercise, immediately after aerobic exercise |
| Effect of acute perioperative exercise: IL-6 | Changes in blood IL-6 concentration during acute perioperative exercise | 10 min before exercise, immediately after aerobic exercise |
| Effect of acute perioperative exercise: IL-8 | Changes in blood IL-8 concentration during acute perioperative exercise | 10 min before exercise, immediately after aerobic exercise |
| Effect of acute perioperative exercise: IL-10 | Changes in blood IL-10 concentration during acute perioperative exercise | 10 min before exercise, immediately after aerobic exercise |
| Effect of acute perioperative exercise: Interferon- γ | Changes in blood interferon- γ concentration during acute perioperative exercise | 10 min before exercise, immediately after aerobic exercise |
| Effect of acute perioperative exercise: C-reactive protein | Changes in blood C-reactive protein concentration during acute perioperative exercise | 10 min before exercise, immediately after aerobic exercise |
| Effect of acute perioperative exercise: Leukocyte differential counts | Changes in blood leukocyte cell counts (total and per type [eosinophils, basophils, lymphocytes, monocytes, neutrophils]) during acute perioperative exercise | 10 min before exercise, immediately after aerobic exercise |
| Effect of acute perioperative exercise: Natural killer cells | Changes in blood natural killer cell count during acute perioperative exercise | 10 min before exercise, immediately after aerobic exercise |
| Effect of acute perioperative exercise: T cells | Changes in blood T cell count during acute perioperative exercise | 10 min before exercise, immediately after aerobic exercise |
| Effect of acute perioperative exercise: Adrenocorticotropic hormone (ACTH) | Changes in blood ACTH concentration during acute perioperative exercise | 10 min before exercise, immediately after aerobic exercise |
| Effect of acute perioperative exercise: Cortisol | Changes in blood cortisol concentration during acute perioperative exercise | 10 min before exercise, immediately after aerobic exercise |
| Effect of acute perioperative exercise: Adrenaline | Changes in blood adrenaline concentration during acute perioperative exercise | 10 min before exercise, immediately after aerobic exercise |
| Effect of acute perioperative exercise: Noradrenaline | Changes in blood noradrenaline concentration during acute perioperative exercise | 10 min before exercise, immediately after aerobic exercise |
| LPS-induced IL-6 production of whole blood | Changes in concentation of IL-6 in LPS-stumulated whole blood | Baseline, after resection, postoperative day 1, postoperative day 3, postoperative day 15, 8 weeks after discharge |
| LPS-induced TNF-a production of whole blood | Changes in concentation of TNF-a in LPS-stumulated whole blood | Baseline, after resection, postoperative day 1, postoperative day 3, postoperative day 15, 8 weeks after discharge |